Marika Cinausero

TL;DR: In this article, the authors discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments and discuss therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of the disease in the next future.

TL;DR: High percentage of patients with luminal-like MBC received CT as first-line therapy in real-life, and the choice was mainly driven by age and site of metastases, with the limitations of a non-randomized comparison.

TL;DR: It is crucial to identify biomarkers that would enable the selection of patients who might benefit from combination treatment with ER and AR inhibitors, and to identify targets that seem to be involved in resistance to hormonal treatment.

TL;DR: The role of sarcopenia in different phases of GC progression is described to provide oncologists and surgeons dealing with GC patients with a useful tool for comprehensive assessment and timely management of this potentially life-threatening condition.

TL;DR: Plasmatic LDH and its variation during first-line treatment predict PFS and OS in MBC, providing independent prognostic information.